Health Trials

Long-term Follow-up of Subjects Treated With CAR T Cells

ConditionsLong Term Adverse EffectsCAR-TDuty to Follow UpAdultProgression-Free SurvivalDisease-Free SurvivalOverall Survival
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMarcela V. Maus, M.D.,Ph.D.

About this trial

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).

Eligibility criteria

Qualifiers

Provision of voluntary written informed consent by subject

CAR T cells were administered in DF/HCC IRB corresponding main study

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Disease assessments
  • Tumor Biopsy
  • Blood test

Treatment groups

45 Participants
are divided into 1 treatment group

Sponsors and collaborators

Marcela V. Maus, M.D.,Ph.D.

Lead sponsor

Massachusetts General Hospital

Sponsor institution

Source ClinicalTrials.gov